GB268

PD-1/CTLA-4/VEGF trispecific antibody · Genor Biopharma Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GB268, covering 2025-04-30 to 2025-04-30. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors [Phase 1]

See pricing